Site Search

You searched for "hepatitis D"

• The Veterans Administration Ignores an Enemy on the Homefront: Hepatitis B

  Courtesy of the U.S. Defense Health Agency. With Veterans Day comes reports about the lack of adequate mental health care for men and women returning from war. There is another, invisible health issue threatening veterans of all ages--hepatitis B. Few veterans have ever been screened or treated for hepatitis B though their infection rate is four-times the national average. The percentage of veterans infected with hepatitis B may actually be higher, but no one knows. Only 15 percent of U.S. veterans have ever been screened for hepatitis B. Among the few screened and diagnosed with chronic hepatitis B, only 25 percent have received antiviral treatment and only 13 percent have been screened for liver cancer. “While other chronic viral infections, such as hepatitis C and HIV, have received tremendous educational efforts,” said researcher David E. Kaplan, MD, “hepatitis B has received far less attention.” Kaplan and a team of Veterans Administration and University of Pennsylvania researchers authored the study that found woefully inadequate screening and treatment for veterans with hepatitis B. The veterans’ experience of inadequate hepatitis B screening and care is not uncommon in the U.S. Repeated studies find that in the private sector, a large percentage of people with chronic hepatitis B also never get the monitoring and drugs treatment they. It’s inexcusable that our flawed civilian health care system does not provide proper hepatitis B treatment, and it’s reprehensible that the VA system that knows many of its patients have hepatitis B and C renders such inadequate care. About 10 percent of all veterans treated by the Veterans Administration Health Administration today have hepatitis C, and at least 35 percent of them are co-infected with hepatitis B. Recent recruits may be immunized against hepatitis B, but millions who fought in earlier conflicts were not and are now infected. Veterans' high hepatitis B infection rate should surprise no one. The

  http://www.hepb.org/blog/the-veterans-administration-ignores-an-enemy-on-the-homefront-hepatitis-b/
• Want to Avoid Liver Cancer? There Are Things You Can Control

  Image courtesy of FreeDigitalPhotos.net We who live with hepatitis B know that avoiding alcohol and cigarettes go a long way toward reducing our risk of liver cancer. But there are new threats emerging. Researchers are finding that obesity, diabetes and developing fatty liver from unhealthy food and a sedentary lifestyle can be just as dangerous to our livers. In a recent study, published in the Journal of Hepatology, researchers found: If you have chronic hepatitis and are obese with a fatty liver, your liver cancer risk increases 1.5 to 4.5 times And, if you have hepatitis B and diabetes, your liver cancer risk climbs two- to three-fold. This is a sobering realization that our lifestyle and our weight matter a lot when it comes to how long we will live. We may like to think we won’t develop liver cancer because our viral load is low or our liver tests don’t show any damage, but sitting all day and over-eating are just as dangerous. While the majority of people who develop liver cancer have severe liver scarring (called cirrhosis) from viral hepatitis, studies are finding a growing number of liver cancers in people who don’t have hepatitis B but do have fatty liver and diabetes. You add fatty liver or diabetes to hepatitis B, and our risk of liver cancer skyrockets. While we may not be able to control our viral loads or hepatitis B infection, we can control our diet and how much we exercise. Eat more fruits and vegetables Studies consistently find that too much fat and sugar increase liver cancer significantly in people living with hepatitis B and C. People who eat lots of proteins and fats can develop fatty liver, which occurs when 10 percent of our livers are made up of fat from unhealthy diets. “There is growing evidence that adherence to a healthy diet plays a role in delaying (liver cancer) development in at-risk populations,” researchers wrote in a recent article published in the September 2015 issue of the Journal of Hepatology. Studies find

  http://www.hepb.org/blog/want-to-avoid-liver-cancer-there-are-things-we-can-control/
• Your Doctor Not Screening You for Liver Cancer? Time for a Talk

  Image courtesy of FreeDigitalPhotos.net The longer we have hepatitis B, the higher our risk of developing liver cancer. With every decade of life, our liver cancer risk increases 2.7-times, according to a report on Viral Hepatitis in the Elderly published in the American Journal of Gastroenterology. But current medical guidelines don’t spell out exactly when liver cancer testing should begin in many hepatitis B patients who don't have liver damage (cirrhosis) or a family history of liver cancer, and are not of Asian or African descent. Age is clearly an important factor when it comes to liver cancer, “… but current guidelines only provide age-specific recommendations for (liver cancer) surveillance in hepatitis B carriers of Asian ethnicity (men over age 40 and women over age 50),” a team of University of Miami and Veterans Affairs researchers wrote in the journal article. Current medical guidelines are clear that anyone with cirrhosis (liver scarring) should be screened twice a year or more frequently for liver cancer, using ultrasound examinations and an alpha fetoprotein (AFP) test, which is a blood test that is moderately successful at identifying cancerous tumors. There’s good reason for this mandate--about 80 percent of people diagnosed with liver cancer also have cirrhosis. The guidelines also state that patients who have a family history of liver cancer, are co-infected with HIV or hepatitis C or who are young males of African descent should also be tested for cancer at any age. But many of us don’t have those “risk factors,” including cirrhosis, but we are still at risk of liver cancer because we’ve had hepatitis B for decades. Our liver cancer risk is much lower than if we have cirrhosis, but it’s still there. As doctors debate whether these guidelines should be changed to promote earlier screening, here are some questions to review with your doctor to determine if you should be screened for liver cancer: How many years have

  http://www.hepb.org/blog/your-doctor-not-screening-you-for-liver-cancer-time-for-a-talk/
• Get Tested for Liver Cancer, Your Life May Depend on It

  Image courtesy of David Castillo Dominici at FreeDigitalPhotos.net October is Liver Cancer Awareness Month. It may be a sleeper of a event when compared to other health campaigns, but for us who live with viral hepatitis, it’s an uncomfortable but critical reminder of the importance of monitoring our liver health to prevent cancer. Viral hepatitis, especially B and C, are viral infections that can cause liver cancer  (also called hepatocellular carcinoma or HCC.) Researchers are still studying why some people are more prone to liver cancer, but we who live with chronic hepatitis B or C have a 25 to 40 percent lifetime risk of developing liver cancer. The infection, which hijacks our liver cells to manufacture more virus, causes inflammation, scarring and even cancer as the liver cells grow out of control. The longer we are infected with viral hepatitis, the higher our risk of developing liver cancer. While liver cancer often occurs in people with cirrhosis (severe liver scarring), some of us develop cancer without cirrhosis. Liver cancer is also a threat to us who are overweight and have hepatitis B or C. If you have viral hepatitis and are overweight with fatty liver disease, your risk of liver cancer more than doubles. Today, 20 percent of Americans have fatty liver disease (also called non-alcoholic fatty liver disease or NAFLD). These are all reasons why we must be willing to save our own life and get checked for liver cancer regularly. Getting screened gives you information about your body. If cancer is present, wouldn’t you rather know about it sooner, when it’s still treatable? Medical guidelines currently recommend regular screening in hepatitis B-infected men starting at age 40 and in women at age 50. But there are also people who should get cancer screening sooner, including: Anyone with cirrhosis and/or a family history of liver cancer People of Asian and Pacific Islander descent. Liver cancer is the third-leading cause of cancer deaths among

  http://www.hepb.org/blog/get-tested-for-liver-cancer-your-life-just-might-depend-on-it/
• Growing Older with Hepatitis B: Prevention and Precautions Still Matter

  Image courtesy of Ambro at FreeDigitalPhotos.net Most people living with chronic hepatitis B today are over age 50, and like their younger counterparts, they need to prevent spreading hepatitis B to their sexual partners, housemates, and neighbors in assisted living facilities. You’re never too old for safe sex: You may not have to worry about pregnancy any more, but you still need to protect yourself and your partner against sexually transmitted diseases such as hepatitis B. Using a condom (and keeping a barrier between you and potentially infectious body fluids) is essential because many seniors have not been immunized against hepatitis B. The widespread marketing of erectile dysfunction drugs allows for sex by older men, and thinning and dryness of vaginal tissue in older women may raise their risk of infection during intercourse. Seniors see doctors more often than young people, but they're less likely to discuss sex and ask about (or use) safe sex practices. According to the U.S. Centers for Disease Control and Prevention (CDC), syphilis, chlamydia and HIV infections are rising again, and about one-quarter of newly reported HIV infections are in people age 55 and older. If you live with hepatitis B, make sure you practice safe sex and your partner is vaccinated. You’re never too old for the hepatitis B vaccine. However, as our immune systems age, our response to immunizations can weaken. The hepatitis B vaccine contains a single protein (antigen) from the virus. It triggers the immune system to develop antibodies to fight infection if we are ever infected with the real virus. But sometimes, our aging immune systems don’t produce enough antibodies after vaccination to eradicate the infection. If you or your partner are getting immunized against hepatitis B, about one or two months after you get the last dose, see your doctor and get tested for hepatitis B antibodies (called titers). If you don't have enough antibodies to fight infection, you

  http://www.hepb.org/blog/growing-older-with-hepatitis-b-prevention-and-precautions-still-matter/
• Is there a cure for hepatitis B?

  There is no cure or medication that totally eliminates the virus or makes HBsAg negative, but there is hope. There are approved therapies for hepatitis B and many in development. First-line therapies in the U.S. and globally are entecavir, tenofovir (TDF) and tenofovir (TAF), which are antivirals. Sometimes, pegylated interferon is used. These drugs control and manage the virus and reduce potential liver damage. The virus is suppressed, liver enzymes and liver function tests may normalize and the liver is better able to heal. In rare cases, they may even get rid of the virus (HBsAg negative). You might be interested in the recent Commentary on the Cure by Dr. Timothy Block, president of the Hepatitis B Foundation; Dr. Chari Cohen, our senior vice president; and Maureen Kamischke, the Foundation's patient engagement and consult specialist. You might also listen to this podcast by HBF’s Dr. Tim Block, the co-founder of the Hepatitis B Foundation about efforts to find a cure, and how the time is right for these great medical discoveries to be achieved sometime soon. For a complete list of FDA-approved drugs and other promising drugs in development for hepatitis B, visit our Drug Watch page. Additional Resources: Progress toward a cure podcast Adults living with hepatitis B Learn more about clinical trials and new drugs in development here Learn about the drug development process here   Find more Frequently Asked Questions here.    Page updated 02/09/2022

  https://www.hepb.org/what-is-hepatitis-b/faqs/is-there-a-cure-for-hepatitis-b/
• Hepatitis B community leaders convene to address eliminating hepatitis B during COVID-19 pandemic

  Doylestown, Pa., Nov. 30, 2020 – Hep B United, a national coalition established by the Hepatitis B Foundation (HBF) and the Association of Asian Pacific Community Health Organizations (AAPCHO) to address the silent epidemic of hepatitis B, will host its eighth annual (and first virtual) summit Dec. 2-4. The event will bring together nearly 200 community leaders, advocates and people living with hepatitis B to promote screening and prevention strategies and advocate for equitable access to health care. Hepatitis B is caused by a virus and is the world’s most common, serious liver infection. It also is the deadliest vaccine-preventable disease, with nearly 900,000 people dying each year from hepatitis B-related disease worldwide. In the United States, an estimated 2.2 million Americans are chronically infected with hepatitis B, yet most do not know it. Without early diagnosis and intervention, one in four people living with hepatitis B will die prematurely from liver failure or liver cancer. “Every year, the Hep B United summit brings together partners around the country to share best practices towards the elimination of hepatitis B,” Chari Cohen, DrPH, MPH, senior vice president of the Hepatitis B Foundation and co-chair of Hep B United, said. “The COVID-19 global pandemic has negatively impacted hepatitis B testing and vaccination programs. We look forward to having important conversations at the summit about strategies to continue critical community-based hepatitis B prevention and outreach programs.” The Hep B United summit is the largest convening of hepatitis B leaders from community coalitions, national nonprofit organizations, individuals and family members affected by hepatitis B, and public health agencies in the United States. Hep B United is comprised of nearly 50 community coalitions across the country located in 29 cities, 22 states and Washington, D.C. The summit’s theme, “Standing Up for Hepatitis B: Creative Collaborations to Amplify Awareness, Access, and Equity,” features sessions that share innovative local, national and global programs to prevent, diagnose and treat hepatitis B, including implementing screening and vaccination programs during the ongoing COVID-19 global pandemic. The summit also will include sessions on the hepatitis B cure, how bias and racism affect health care, and voices from #justB, the Hepatitis B Foundation’s national storytelling campaign that tells the personal stories of people affected by hepatitis B to increase public awareness and combat stigma and discrimination. "The Hep B United Summit convenes community leaders and other experts across the country at the frontlines of combating hepatitis B," said Jeffrey Caballero, executive director of AAPCHO and co-chair of Hep B United. "The Summit is needed now more than ever amid the COVID-19 pandemic, which has exacerbated the challenges of those most impacted by hepatitis B, including Asian Americans and Pacific Islanders. Critical conversations, community engagement and advocacy best practices among the Hep B United coalition members spark the action needed to continue our work together to end this 'silent' epidemic and ensure equitable access to health care for our communities." During the Summit’s reception on Dec. 4, Hep B United will present Corinna Dan, RN, MPH, former Senior Policy Advisor, U.S. Department of Health and Human Services Office on Infectious Disease and HIV/AIDS Policy, with the first Hepatitis B Federal Champion Award. Hep B United also will present 2020 Hep B Champion Awards to nine community leaders and organizations in recognition of their collaborative and successful initiatives to address hepatitis: Amy Shen Tang, MD, Director of Immigrant Health, Northeast Medical Services, San Francisco Asian Health Coalition, Chicago Bright Ansah, #justB Storyteller, Maryland Chioma Nnaji, MPH, MEd, Project Director, Multicultural AIDS Coalition, Boston Coalition Against Hepatitis in People of African Origin (CHIPO) New York City David Urick, #justB Storyteller, Ypsilanti, MI Farma Pene, Community Projects Coordinator, Bureau of Communicable Diseases, NYC Department of Health & Mental Hygiene, New York City Joe Balestreri, #justB Storyteller, Santa Rosa, CA Richard So, MPH, MPA, Executive Director, San Francisco Hep B Free-Bay Area, San Francisco ### About Hepatitis B: Hepatitis B is one of the world’s most common infections and the primary cause of liver cancer, which is the second-leading cause of cancer death in the world. Up to 292 million are chronically infected, and almost 1 million people die each year from hepatitis B-related liver failure and liver cancer. In the U.S., one in 20 Americans has been infected with hepatitis B, and up to 2.2 million are chronically infected. The hepatitis B virus is transmitted through blood, unprotected sex, unsterile needles, and from an infected mother to her newborn due to blood exchange during delivery. Although hepatitis B is preventable and treatable, there is still no complete cure for this deadly liver infection. About Hep B United: Hep B United is a national coalition established by the Hepatitis B Foundation and the Association of Asian and Pacific Community Health Organizations (AAPCHO) to address the public health challenge of hepatitis B by increasing awareness, screening, vaccination and linkage to care for all Americans, with a particular focus on Asian-American and Pacific Islander populations that are disproportionately impacted. To learn more, visit www.hepbunited.org. About the Hepatitis B Foundation: The nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy, the Hepatitis B Foundation is based in Doylestown, Pa., with an office in Washington, D.C. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900. To donate, contact Jean Holmes at 215-489-4900 or jean.holmes@hepb.org. About the Association of Asian Pacific Community Health Organization: The Association of Asian Pacific Community Health Organization (AAPCHO) is a national association of community health organizations dedicated to promoting advocacy, collaboration, and leadership that improves the health status and access of Asian Americans, Native Hawaiian, and other Pacific Islanders in the United States. To learn more, visit www.aapcho.org.

  https://www.hepb.org/news-and-events/news-2/hepatitis-b-community-leaders-convene-to-address-eliminating-hepatitis-b-during-covid-19-pandemic-2/
• "الحَمْل والتهاب الكبد "ب

  Should I be tested for hepatitis B if I am pregnant? Yes, ALL pregnant women should be tested for hepatitis B!  If you are pregnant, be sure your doctor tests you for hepatitis B before your baby is born. Why are these tests so important for pregnant women? If you test positive for hepatitis B and are pregnant, the virus can be passed on to your newborn baby during your pregnancy or during delivery. If your doctor is aware that you have hepatitis B, he or she can make arrangements to have the proper medications in the delivery room to prevent your baby from being infected. If the proper procedures are not followed, your baby has a 95% chance of developing chronic hepatitis B! Will a hepatitis B infection affect my pregnancy? A hepatitis B infection should not cause any problems for you or your unborn baby during your pregnancy.  It is important for your doctor to be aware of your hepatitis B infection so that he or she can monitor your health and so your baby can be protected from an infection after it is born. If I am pregnant and have hepatitis B, how can I protect my baby? If you test positive for hepatitis B, your doctor should also test you for the hepatitis B e-antigen (HBeAg), and if positive, you should have a hepatitis B viral load blood test (HBV DNA quantification). In some cases, the laboratory test results may show a very high viral load. In these cases, your physician may recommend that you take an oral antiviral drug in the third trimester, which is safe to take to reduce the risk of infecting your newborn at birth.  If you test positive for hepatitis B, then your newborn must be given two shots immediately in the delivery room: First dose of the hepatitis B vaccine One dose of hepatitis B immune globulin (HBIG) If these two medications are given correctly within the first 12 hours of life, a newborn has more than a 90% chance of being protected against a lifelong hepatitis B infection.  You must make sure your baby receives the remaining 2-3 doses of the hepatitis B vaccine according to schedule. All doses must be completed in order for your infant to be fully protected against hepatitis B. It is also important that a baby born to an HBV-positive mother receive post-vaccination serologic testing at 9-12 months to confirm the baby is protected against HBV and is not infected. Tests include the HBsAg and anti-HBs titer test. There is no second chance to protect your newborn baby!   Vaccination Outside the United States In many countries, the pentavalent vaccine, a combination 5-in-one vaccine that protects against five diseases (diphtheria, pertussis, tetanus, Hib and hepatitis B) may be given to babies more than 6 weeks of age, and can be given up to 1 year of age. The first dose is given at 6 weeks, and the second and third doses are given at 10 and 14 weeks of age. The pentavalent vaccine may be made available free of charge with the support of Gavi, the Vaccine Alliance. Check the Gavi country hub to see the resources and immunizations that may be available: http://www.gavi.org/country/. For babies born to mothers with hepatitis B, waiting for the first dose of the pentavalent vaccine is too late and will NOT protect the baby from becoming infected during birth or within the first six weeks of life. A woman who is hepatitis B positive is likely to pass the virus on to her baby, who will then be chronically infected.  WHO recommends the hepatitis B vaccine within 24 hours of birth for ALL babies. Plan ahead and inquire about the availability and cost of the monovalent (single), birth dose of the vaccine, as it is not a Gavi provided immunization. This is particularly important to women who are positive for hepatitis B.   If you are unsure of your hepatitis B status, please be sure your doctor tests you for hepatitis B! For babies NOT receiving the pentavalent vaccine, the first dose of the monovalent, HBV vaccine must be given within 12 hours of birth, followed by the remaining 2-3 doses of the hepatitis B vaccine according to schedule. For babies receiving the pentavalent vaccine, the first, monovalent dose of the hepatitis B vaccine is given within 12 hours of birth, and the second and third doses of the HBV vaccine will be included in dose 1 and dose 2 of the pentavalent vaccine. *Note: CDC recommends both the first shot of the HBV vaccine and HBIG within 12 hours of birth. HBIG may not be available in all countries.  Do I need treatment during my pregnancy? A hepatitis B infection should not cause any problems for you or your unborn baby during your pregnancy. It is important for your doctor to be aware of your hepatitis B infection so that he or she can monitor your health and so your baby can be protected from an infection after it is born. If you live outside of the U.S. and are unsure of your hepatitis B status, please ask your doctor to test you for hepatitis B. Failure of the birth dose of the HBV vaccine and HBIG may occur in women who are HBeAg positive and have a very high viral load, allowing for the transmission of hepatitis B to your baby. All women who are diagnosed with hepatitis B in pregnancy should be referred for follow up care with a physician skilled at managing hepatitis B infection. Your physician should perform additional laboratory testing, including hepatitis B e-antigen, HBV DNA level, and liver function tests (ALT).  A virus level greater than 200,000 IU/mL or 1 million cp/ml indicates a level where the combination of the birth dose of the vaccine and HBIG may fail. First-line, antiviral therapy with tenofovir may be recommended to reduce the viral load prior to birth. Tenofovir has been shown to be safe both during pregnancy and for breastfeeding mothers. In cases where tenofovir is not effective, doctors may prescribe telbivudine or lamivudine. Antiviral treatment begins at 28-32 weeks and continues 3 months postpartum.  Do I need treatment after my pregnancy?  If you are prescribed antivirals during pregnancy, you should have your ALT (SGPT) monitored every 3 months for 6 months. This will help determine if you should continue antiviral treatment. Please do not discontinue your antiviral medication unless the doctor advises you to, based upon test results. For most women whose follow up testing shows no signs of active disease, your physician will recommend regular monitoring with a liver specialist.  In all cases, it is very important that your obstetrician and your newborn’s pediatrician, are aware of your hepatitis B status to ensure that your newborn receives the proper vaccines at birth to prevent a lifelong hepatitis B infection, and that you receive appropriate follow up care.  Can I breastfeed my baby if I have hepatitis B? The benefits of breastfeeding outweigh the potential risk of infection, which is minimal.  In addition, since it is recommended that all infants be vaccinated against hepatitis B at birth, any potential risk is further reduced. There is data that shows that tenofovir, which may be prescribed to manage hepatitis B, is safe for breastfeeding women.   هل يجب أن أخضع لاختبار التهاب الكبد "ب" إذا كنت حاملاً؟ نعم، يجب أن تخضع "جميع" الحوامل لاختبار التهاب الكبد "ب"! إذا كنت حاملاً، فاحرصي على أن يُجري لك طبيبك اختبار التهاب الكبد "ب" قبل ولادة طفلك. لماذا تكون هذه الاختبارات مهمة للغاية للحوامل؟ إذا كانت نتيجة اختبار التهاب الكبد "ب" الذي خضعت له إيجابية وكنتِ حاملاً، يمكن أن ينتقل الفيروس إلى طفلك الوليد أثناء فترة الحمل أو أثناء الولادة. إذا كان طبيبك على علم بأنك مصابة بالتهاب الكبد "ب"، يمكنه اتخاذ الترتيبات اللازمة لتوفير الأدوية المناسبة في غرفة الولادة لمنع إصابة طفلك بالعدوى. في حالة عدم اتباع الإجراءات الصحيحة، فإن طفلك مُعرّض بنسبة 95% للإصابة بالتهاب الكبد "ب" المزمن! هل ستؤثر عدوى التهاب الكبد "ب" على حملي؟ ينبغي ألا تتسبب عدوى التهاب الكبد "ب" في أي مشكلات لك أو لجنينك أثناء فترة الحمل. من المهم أن يكون طبيبك على علم بإصابتك بعدوى التهاب الكبد "ب" حتى يتمكن من متابعة حالتك الصحية، وبالتالي يكون طفلك محميًا من الإصابة بالعدوى بعد ولادته. إذا كنت حاملاً ومصابة بالتهاب الكبد "ب"، فكيف يمكنني حماية طفلي؟ إذا كانت نتيجة اختبار التهاب الكبد "ب" الذي خضعت له إيجابية، يجب أن يُجري لك طبيبك كذلك اختبار الكشف عن المستضد "e" لالتهاب الكبد "ب" (HBeAg)، وإذا كانت نتيجة الاختبار إيجابية، يجب أن تُجري اختبار دم للحِمل الفيروسي لالتهاب الكبد "ب" (التقدير الكمي للحمض النووي (DNA) لفيروس التهاب الكبد "ب" (HBV)). وفي بعض الحالات، يمكن أن تُظهر نتائج الاختبارات المَعملية وجود حِمل فيروسي عالٍ للغاية. وقد يوصي الطبيب في هذه الحالات بتناولك دواءً مضاد للفيروس يؤخذ عن طريق الفم في الثلث الأخير من فترة الحَمل، والذي يكون من الآمن تناوله في سبيل تقليل خطر إصابة طفلك عند الولادة.  إذا كانت نتيجة اختبار التهاب الكبد "ب" الذي خضعت له إيجابية، يجب إعطاء طفلك حديث الولادة حقنتين على الفور في غرفة الولادة: الجرعة الأولى من لقاح التهاب الكبد "ب" جرعة واحدة من الجلوبيولين المناعي لالتهاب الكبد "ب" (HBIG) إذا تم إعطاء هذين الدواءين بشكل صحيح خلال أول 12 ساعة من حياة الطفل حديث الولادة، فإن احتمالية أن يكون محميًا من الإصابة بعدوى التهاب الكبد "ب" مدى الحياة تفوق 90%.  ويجب عليك الحرص على أن يتناول طفلك الجرعتين أو الجرعات الثلاث المتبقية من لقاح التهاب الكبد "ب" وفقًا للجدول الزمني المُقرر. ويجب إكمال جميع الجرعات لحماية طفلك تمامًا من التهاب الكبد "ب". وكذلك، من المهم إجراء اختبارات مصلية للطفل المولود لأم مصابة بفيروس التهاب الكبد "ب" بعد تلقي اللقاح عند عمر 9-12 شهرًا للتأكد من أن الطفل محمي من فيروس التهاب الكبد "ب" وأنه لن يصاب به. الاختبارات تتضمن اختبارًا للكشف عن المستضد السطحي لفيروس التهاب الكبد "ب" (HBsAg) واختبارًا للكشف عن عيار الجسم المضاد لفيروس التهاب الكبد "ب". ليست هناك فرصة ثانية لحماية طفلك حديث الولادة!   اللقاحات خارج الولايات المتحدة في العديد من الدول، يمكن إعطاء اللقاح خماسي التكافؤ، وهو تركيبة من خمسة لقاحات في لقاح واحد يحمي من الإصابة بخمسة أمراض (الدفتيريا والسعال الديكي والتيتانوس والمُسْتَدْمِية النزلية النوع "ب" والتهاب الكبد "ب")، للأطفال الذين تزيد أعمارهم عن 6 أسابيع، ويمكن أن يُعطى حتى بلوغ سن العام الواحد. تُعطى الجرعة الأولى عندما يكون عمر الطفل 6 أسابيع، والجرعتين الثانية والثالثة في عمر 10 أسابيع و14 أسبوعًا. ويمكن توفير اللقاح خماسي التكافؤ مجانًا بدعم من Gavi، وهو التحالف العالمي للقاحات والتحصين. ارجع إلى مركز البلد التابع للتحالف العالمي للقاحات والتحصين Gavi للاطلاع على الموارد والتحصينات التي قد تكون متوفرة: /http://www.gavi.org/country. بالنسبة للأطفال المولودين لأمهات مصابات بالتهاب الكبد "ب"، فإن انتظار الجرعة الأولى من اللقاح خماسي التكافؤ يكون متأخرًا للغاية و"لن" يحمي الطفل من الإصابة أثناء الولادة أو خلال الأسابيع الستة الأولى من حياته. فمن الممكن أن تنقل المرأة المصابة بفيروس التهاب الكبد "ب" الفيروس إلى طفلها الذي سيصاب عندئذ بالعدوى المزمنة.  توصي منظمة الصحة العالمية (WHO) بتلقي لقاح التهاب الكبد "ب" خلال 24 ساعة من الولادة لجميع المولودين. فيجب التخطيط للمستقبل والسؤال عن مدى توافر جرعة اللقاح أحادي التكافؤ (المفرد) المتلقاة عند الولادة وتكاليفها، لأن هذا التحصين لا يوفره التحالف العالمي للقاحات والتحصين Gavi. وهذا أمر مهم خاصةً للنساء المصابات بالتهاب الكبد "ب". إذا لم تكن متأكدًا مما إذا كنت مصابًا بالتهاب الكبد "ب"، يُرجى الحرص على أن يُجري لك طبيبك اختبارًا للكشف عن التهاب الكبد "ب"! وفيما يتعلق بالأطفال الذين "لا" يتلقون اللقاح خماسي التكافؤ، يجب إعطاء الجرعة الأولى من لقاح التهاب الكبد "ب" (HBV) أحادي التكافؤ خلال 12 ساعة من الولادة، متبوعة بالجرعتين أو الجرعات الثلاث المتبقية من لقاح التهاب الكبد "ب" وفقًا للجدول الزمني المقرر. أما بشأن الأطفال الذين يتلقون اللقاح خماسي التكافؤ، فيتم إعطاء الجرعة الأولى من لقاح التهاب الكبد "ب" أحادي التكافؤ خلال 12 ساعة من الولادة، وسيتم تضمين الجرعتين الثانية والثالثة من لقاح التهاب الكبد "ب" في الجرعة 1 والجرعة 2 من اللقاح خماسي التكافؤ. *ملاحظة: توصي مراكز مكافحة الأمراض والوقاية منها (CDC) بإعطاء الجرعة الأولى من لقاح التهاب الكبد "ب" (HBV) والجلوبيولين المناعي لالتهاب الكبد "ب" (HBIG)خلال 12 ساعة من الولادة. وقد لا يكون الجلوبيولين المناعي لالتهاب الكبد "ب" متوفرًا في جميع البلاد. هل أحتاج إلى تناول علاجات معينة أثناء فترة حملي؟ ينبغي ألا تتسبب عدوى التهاب الكبد "ب" في أي مشكلات لك أو لجنينك أثناء فترة الحمل. من المهم أن يكون طبيبك على علم بإصابتك بعدوى التهاب الكبد "ب" حتى يتمكن من متابعة حالتك الصحية، وبالتالي يكون طفلك محميًا من الإصابة بالعدوى بعد ولادته. إذا كنت تعيشين خارج الولايات المتحدة ولست متأكدة من إصابتك بالتهاب الكبد "ب"، يُرجى أن تطلبي من طبيبك أن يُجري لك اختبارًا للكشف عن التهاب الكبد "ب". يمكن ألا تكون جرعة لقاح التهاب الكبد "ب" والجلوبيولين المناعي لالتهاب الكبد "ب" المتلقاة عند الولادة مجدية لدى النساء اللاتي تكون نتيجة اختبار الكشف عن المستضد "e" لالتهاب الكبد "ب" (HBeAg) الذي خضعن له إيجابية ولديهن حِمل فيروسي مرتفع للغاية، مما يسمح بنقل التهاب الكبد "ب" إلى الطفل. يجب إحالة جميع النساء اللاتي تم تشخيص إصابتهن بالتهاب الكبد "ب" أثناء الحمل للحصول على رعاية متابعة لحالتهن تحت إشراف طبيب متمرس في السيطرة على عدوى التهاب الكبد "ب". ويتعين أن يُجري طبيبك اختبارات معملية إضافية، بما في ذلك اختبار الكشف عن المستضد e لالتهاب الكبد "ب" ومستوى الحمض النووي (DNA) لفيروس التهاب الكبد "ب" واختبار وظائف الكبد (ناقلة أمين الألانين (ALT)).  يشير مستوى الفيروس الذي يزيد عن 200000 وحدة دولية/مل (IU/mL) أو مليون نسخة/مل (cp/ml) إلى احتمالية لعدم نجاح تركيبة جرعة اللقاح والجلوبيولين المناعي لالتهاب الكبد "ب" (HBIG) المتلقاة عند الولادة. قد يُوصى بالعلاج بواحد من الخيارات الأولى من مضادات الفيروسات باستخدام عقار تينوفوفير لتقليل الحِمل الفيروسي قبل الولادة. لقد ثبت أن تينوفوفير آمن أثناء فترة الحمل وعلى صحة الأمهات المرضعات. وفي الحالات التي يكون فيها عقار تينوفوفير غير فعال، يمكن أن يصف الأطباء تناول دواء تيلبيفودين أو لاميفودين. يبدأ العلاج بمضادات الفيروس عند عمر من 28 إلى 32 أسبوعًا ويستمر لمدة 3 أشهر من بعد الولادة.  هل أحتاج إلى علاج بعد انتهاء فترة حملي؟ إذا وُصِفتْ لك مضادات الفيروس أثناء الحمل، يجب أن تخضعي لاختبار ناقلة أمين الألانين (ALT) (ويسمى أيضًا مصل الغلوتاميك للبيروفيك (SGPT)) كل 3 أشهر لمتابعة حالتك وذلك لمدة 6 أشهر. سيساعد ذلك في معرفة ما إذا كان يجب عليك الاستمرار في العلاج بمضادات الفيروس. يُرجى عدم التوقف عن تناول الأدوية المضادة للفيروس ما لم ينصحك الطبيب بذلك استنادًا إلى نتائج الاختبارات التي تخضعين لها. وفيما يتعلق بالنساء اللاتي لا تُظهر اختبارات المتابعة الخاصة بهن أيًّا من علامات المرض النشط، فإن طبيبك سيوصي بمتابعة حالتك بصورة منتظمة مع أخصائي كبد.  ومن المهم للغاية في جميع الحالات أن يكون طبيب الولادة وطبيب الأطفال حديثي الولادة المتابع لك على علم بإصابتك بالتهاب الكبد "ب" للحرص على أن يتلقى طفلك الوليد اللقاحات المناسبة عند الولادة لمنع إصابته بعدوى التهاب الكبد "ب" لمدى الحياة، وأن تتلقين رعاية متابعة مناسبة.  هل يمكنني أن أرضع طفلي إذا كنت مصابة بفيروس التهاب الكبد "ب"؟ فوائد الرضاعة الطبيعية أكبر مقارنة باحتمالية الإصابة بعدوى، والتي تكون محدودة. علاوة على ذلك، نظرًا إلى أنه يوصى بلقاح جميع الرضع ضد التهاب الكبد "ب" عند الولادة، فإن نسبة وجود أي خطر محتمل تقل بنسبة أكبر. وهناك معلومات تفيد بأن عقار تينوفوفير، الذي يمكن وصفه طبيًا للسيطرة على حالة التهاب الكبد "ب"، آمن للمرأة التي ترضع طفلها طبيعيًا.  

  https://www.hepb.org/languages/arabic/page-596/
• Privacy Policy

  Our Commitment to Privacy The Hepatitis B Foundation (HBF) pledges to protect the privacy of every individual who visits our website at www.hepb.org. Any information collected on this website is used only for the purposes stated. The Hepatitis B Foundation has taken steps to make information received from online visitors as secure as possible against unauthorized access and use. All information is protected by security measures that are regularly reviewed. By visiting www.hepb.org, you accept the practices described in this Privacy Notice. Information Use The Hepatitis B Foundation collects information from users through several points on the website, such as registering for conferences and newsletters, making donations, ordering resource materials, and joining the Liver Specialist Directory. The Hepatitis B Foundation will not share, sell or forward to third parties any individually identifiable personal information (e.g., your e-mail address, name, etc.). The HBF web server routinely collects and stores information provided by your web browser such as the pages visited on our site, the date and time of the visit, the Internet address of the referring site, the IP address or your connection to the Internet, the version of browser used, and the capabilities of the browser. HBF makes no attempt to identify individual visitors from this information. The Hepatitis B Foundation is committed to protecting the privacy of children; we do not knowingly collect personal information from any person under the age of 18. Communications from the Site HBF uses contact information to periodically send email and/or conventionally mailed newsletters dealing with liver health and hepatitis education. If you do not wish to receive email or other free resource materials from HBF, you may choose to opt-out by e-mailing info@hepb.org or calling 215-489-4900. Outside Links This site contains links to other non-HBF sites that are relevant to the issues of hepatitis B. We have chosen these sites carefully but cannot attest to their privacy practices or to the accuracy of their content. We encourage you to be aware when you leave this site and to read the privacy policies of any website that you may visit. Advertising This site does not accept or host any advertisements. Questions Questions regarding this notice should be directed to info@hepb.org or: Hepatitis B Foundation3805 Old Easton RoadDoylestown, PA 18902215-489-4900 (phone)215-489-4920 (fax)

  https://www.hepb.org/privacy-policy/
• Hepatitis B Foundation Welcomes International Leaders to Its Scientific and Medical Advisory Board

  Doylestown, PA (February 2017) -- The Hepatitis B Foundation is pleased to announce that two internationally renowned experts in the area of viral hepatitis have joined its Scientific and Medical Advisory Board. Francis Chisari, MD, recently retired from Scripps Research Institute, and Robert P. Perrillo, MD, FAASLD, of Baylor University Medical Center, were both appointed to the foundation’s distinguished advisory board. “The Hepatitis B Foundation is proud to have Drs. Chisari and Perrillo join our Scientific and Medical Advisory Board,” said Timothy M. Block, PhD, president and co-founder of the Hepatitis B Foundation. “Both are highly accomplished scientists who have made significant contributions to advancing the science and medicine of hepatitis B. Their involvement will strengthen our organization and improve how we serve those with hepatitis B worldwide.”  Dr. Frank Chisari Dr. Chisari recently retired from the Scripps Research Institute where he served as professor and head of the Division of Experimental Pathology in the Department of Molecular and Experimental Medicine. His research is internationally recognized and focused on host-virus interactions that determine the outcome of viral infections, using the hepatitis B virus (HBV) and the hepatitis C virus (HCV) as models. Dr. Chisari has received numerous honors and awards for his scientific achievements, including the Ernst Jung Prize in Medicine, the Rous Whipple Award of the American Society of Investigative Pathology, and the Distinguished Scientific Achievement Award of the American Association for the Study of Liver Diseases. He holds numerous patents, serves on many scientific advisory boards, and is a frequent keynote lecturer. Dr. Chisari received his Medical Degree from Cornell University Medical College and is Board Certified in Internal Medicine and Anatomic Pathology. Dr. Robert Perrillo Dr. Perrillo, senior research hepatologist, Hepatology Division of Baylor University Medical Center in Dallas, and adjunct professor of Medicine, University of Texas Southwestern,is an international opinion leader and educator with more than 200 published papers and a nearly 40 year career of clinical research in hepatitis B. He was the lead investigator of the U.S. multicenter study that described the safety and efficacy of alpha interferon in chronic hepatitis B, which became the first approved drug for hepatitis B in 1992. He was one of first investigators to explore oral nucleoside analogue therapy (adenine arabinoside) to treat hepatitis B in the early 1980’s and the first to publish on adefovir’s efficacy for lamivudine resistant hepatitis B, both in the transplant and non-transplant settings. Dr. Perrillo received his Medical Degree from Georgetown University and completed his Gastroenterology fellowship training at Washington University. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900.   # # #

  https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-welcomes-international-leaders-to-its-scientific-and-medical-advisory-board/